An Indian company launches a vast pharmaceutical manufacturing project in Morocco
This article was automatically translated from HIBAPRESS, the Arabic version:
This article was automatically translated from HIBAPRESS, the Arabic version:
Heba Press
The pharmaceutical industry sector in Morocco is experiencing major development with the announcement by the Indian company Biocon Biologicals of a huge investment in the Kingdom.
The company plans to establish a new production site in Casablanca, with an investment of up to 100 million dirhams, which represents a qualitative leap in the manufacturing of biopharmaceutical products.
The project will focus on the production of advanced, high-value medicines, including treatments for cancer and autoimmune diseases.
This investment aims to meet the needs of Moroccan patients by offering innovative and effective treatments at competitive prices, which helps improve access to healthcare.
This project is expected to create direct and indirect employment opportunities, which will support the national economy.
It will also contribute to the transfer of advanced technologies and expertise to Morocco, as this will strengthen the capacity of the local pharmaceutical industry to keep pace with global innovations.
Biocon Biologics’ entry into the Moroccan market is a strategic step that supports Morocco’s position as a regional biopharmaceutical production hub.
This investment also reflects the growing international confidence in Morocco’s business environment, which strengthens its global competitiveness in the field of high-tech pharmaceutical industries.
